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InﬂammationAllogeneic transplantation can cure many disorders, including sickle cell disease, chronic granulomatous disease
(CGD), severe combined immunodeﬁciency (SCID) and many types of cancers. However, there are several asso-
ciated risks that can result in severe immunological reactions and, in some cases, death. Much of this morbidity
is related to graft versus host disease (GVHD) [1]. GVHD is an immune mediated reaction in which donor T cells
recognize the host as antigenically foreign, causing donor T cells to expand and attack host tissues. The current
method of treating recent transplant patients with immunosuppressants to prevent this reaction has met with
only partial success, emphasizing a need for new methods of GVHD treatment and prevention. Recently, a
novel strategy has emerged targeting adenosine A2A receptors (A2AR) through the use of adenosine agonists.
These agonists have been shown in vitro to increase the TGFβ-induced generation of FoxP3+ regulatory T cells
(Tregs) and in vivo to improve weight gain and mortality as well as inhibit the release of pro-inﬂammatory cyto-
kines in GVHD murine models [2,3]. Positive results involving A2AR agonists in vitro and in vivo are promising,
suggesting that A2AR agonists should be a part of the management of clinical GvHD.
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Biotechnology. This is an open access article under the CC BY license
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Graft versus host disease (GVHD) is an immune driven disorder
where donor T cells react and proliferate in response to host antigens.
This leads to an immune reaction that can affect several target organs
including liver, skin, and the gastrointestinal tract. GVHD remains one
of the leading causes of morbidity andmortality associated with alloge-
neic transplantation in patients and stands as a signiﬁcant barrier to the
broader use of hematopoietic stem cell transplantation (HSCT) [4]. The
current method of GVHD prevention is the use of immunosuppressantsa@gmail.com (K.R. Jones).
behalf of the Research Network of Cincluding calcineurin inhibitors, to reduce the donor T cell reaction to
host tissues. Unfortunately, this treatment is only effective approxi-
mately 50% of the time and can have several dangerous side effects [5].
More recently, an alternate pathway of interest has been the use of
regulatory T cells (Tregs) to increase immune tolerance and prevent
GVHD. Infusion of regulatory T cells has been tried in a number of
studies with varying success and the commonly used immunosuppres-
sant Sirolimus (also known as rapamycin) appears to predominantly
work through Treg generation [6]. Augmenting Treg cells can also be
achieved through the use of adenosine agonists, speciﬁcally A2a receptor
(A2aR) agonists. It has been shown that the development and increase in
immunosuppressive capabilities of Tregs are under adenosinergic regula-
tion and require adenosine receptor activation for their proper functionomputational and Structural Biotechnology. This is an open access article under the CC BY
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increase immune tolerance in several disease models, including ische-
mia, colitis and sickle cell disease [8–11]. This method has also been
shown to have positive effects on Treg numbers and function in GVHD
animal models and to increase overall survival after allogeneic bone
marrow transplantation [2,3]. Based on these promising results, it can
be concluded that A2aR agonists via the induction of Treg formation has
a therapeutic potential for the treatment of GVHD.
2. Graft versus host disease
GVHD has an overall incidence of 35–50% [4] for all transplants. This
incidence is based on patient risk factors, including donor cell source,
age of the patient and pre-transplant conditioning. Acute GVHD pro-
gresses rapidly, typically occurring within 100 days of HSCT. Symptoms
include dermatitis, cutaneous blisters, abdominal pain, persistent nau-
sea and vomiting [12]. At the molecular level, GVHD is divided into
three stages of progression [13]. The ﬁrst stage consists of inﬂammation
damage to host tissues by pre-transplant chemo or radiotherapy condi-
tioning. This inﬂammation causes the release of pro-inﬂammatory cyto-
kines such as IL-1, IL-6, IL-12, and TNF-α. These cytokines activate host
antigen presenting cells (APCs), which triggers the second phase of
acute GVHD. During this phase, donor T cells recognize and react to
host APCs, causing an overall increase in the number of donor-derived
effector T cells, both CD4+ and CD8+ cytotoxic cells [4]. Donor CD4+ T
cells are further skewed towards a Th1 polarization, causing production
of the IL-2 and IFN-γ cytokines. These Th1 cytokines encourage addi-
tional cytotoxic T-cell proliferation and cytokine release, initiating the
tissue damage generally associated with acute GVHD [4,13]. Finally,
during the third phase, further tissue damage occurs due to continuing
expression of pro-inﬂammatory cytokines and donor cytotoxic T cells.
The majority of this damage is a result of the Fas/FasL and perforin/
granzyme B pathways as well as an effect of the activation of additional
macrophages, neutrophils, eosinophils, B cells and T cells. The resulting
induction of apoptosiswithin host tissues leads to the visible tissue dam-
age typical of acute GVHD. Prevention or arrest of this self-destructive
cycle is essential in the development of treatments for GVHD.
Currently, the standard treatment for the prevention of GVHD is the
use of immunosuppressive therapy. Cyclosporin (CsA), and other cal-
cineurin inhibitors like Tacrolimus, are commonly used to prevent
GVHD as they inhibit T-cell proliferation and IL-2 production. Unfortu-
nately, calcineurin inhibitors also have signiﬁcant side effects, including
hypertension, nephrotoxicity, neurotoxicity, and liver cholestasis [1].
Corticosteroids have also been used to suppress the immune response
and reduce inﬂammation, but they are non-speciﬁc and can lead to
opportunistic infections [14]. Thus there is a need for a more targeted
and effective treatment/preventative for GVHD.
3. Adenosine, Foxp3 and the induction of immune tolerance
An important aspect of the human immune system, in addition to
protecting the host from pathogenic invasions, is the ability to suppress
immunological reactions to self-antigens and prevent excessive immune
responses thatmaybecomedamaging to thehost. This activity is primar-
ily mediated by regulatory T cells (Tregs) that specialize in immunosup-
pression [15]. Tregs are characterized as CD4+CD25+ expressing high
levels of the transcription factor forkhead box p3 (FoxP3). There are
two types of Tregs, those that arise in the thymus (natural) and those in
which FoxP3 expression is activated in the periphery (induced) [16].
The importance of Tregs can clearly be seen in mouse models lacking
CD4+CD25+ Tregs and in mice lacking FoxP3 expression. These mice
develop fatal autoimmune diseases, allergies, and immunopathology
characteristic of chronic tissue inﬂammation [17–20]. These changes
have also been observed in human patients lacking proper expression
of the FoxP3 gene (known as immunodeﬁciency, polyendocrinopathy,
X-linked, or IPEX) and results in immune dysregulation leading toseveral autoimmune disorders [21–23]. Because disruption of Treg
function alone is enough to cause dysregulation of self-tolerance,
it can be concluded that Tregs are essential for proper function of
immunosuppression.
The purine nucleoside adenosine is released by many cells in
the body and is producedmainly through the breakdown of ATP. Extra-
cellular adenosine binds to a family of G protein-coupled receptors
expressed on the surface of cells known as adenosine receptors.
These fall into four subtypes including A1R, A2AR, A2BR and A3R [24].
Of particular interest is the A2AR subtype, as it is highly expressed in
the spleen, thymus and brain [25]. This subtype is responsible for
modulation of the inﬂammatory response and has activity on nearly
all inﬂammatory cells. A2A knockout mice have demonstrated the
importance of A2A receptors: the induction of acute hepatitis in A2A
deﬁcient mice results in severe inﬂammatory tissue damage and rein-
forces the non-redundant signiﬁcance of the A2A receptor pathway in
inﬂammation [26].
Recent data has shown that Treg activation and function falls under
the control of extracellular adenosine. Tregs have been shown to express
high levels of CD39 and CD73, which are responsible for the conversion
of ATP toAMP (mediated by CD39) and ultimately adenosine (mediated
by CD73) [27,28]. It also appears that this adenosine, through the aden-
osineA2A receptor pathway, inhibits the activation of effector T cells and
increases the overall number of Tregs, creating an immunosuppressive
effect [7,29]. Because Treg suppressive function is highly regulated by
adenosine and the A2A receptor pathway, it is a natural target for phar-
maceutical development. However, as adenosine non-speciﬁcally binds
to all adenosine receptors, both pro- and anti-inﬂammatory, and has a
short half-life, its therapeutic value has been somewhat limited [30].
More recently, very speciﬁc adenosine A2AR agonists have been devel-
oped and tested in many areas, including cancer, autoimmune diseases
and inﬂammatory disorders [31]. Use of A2AR agonists in the treatment
of a mouse model of acute endotoxemia and sepsis improved mouse
survival and decreased the levels of live bacteria in blood [32]. A2A re-
ceptor activation was also shown to reduce ischemia reperfusion injury
in mice [33]. Because of the success of A2AR agonists in other autoim-
mune and inﬂammatory diseases, interest has increased in the use of
A2AR agonists in the treatment of GVHD.
4. Adenosine, adenosine receptors and their role in GVHD
GVHD is characterized by an immune response of donor T cells to
host tissues, causing tissue inﬂammation and damage. The majority
of the tissue damage in GVHD is due to the activity of alloreactive
T cells, and current data suggests that the inhibition of these cells
can limit morbidity associated with this disorder. To date, there are
several treatments available for T cell reduction, but many of these
have severe side effects, such as an increased incident of infection. In
many diseases, extended administration of adenosine or adenosine
analogs has reduced inﬂammation in tissues including the liver, skin
and gastrointestinal tract with no observed side effects [34,35].
Prolonged oral treatment of a mouse model of colitis with the A2AR
agonist ATL313 attenuated the disease with no major negative out-
comes [9]. In addition, the A2AR agonist ATL146e has been shown
to be effective for the treatment of inﬂammation and renal injury asso-
ciated with diabetic nephropathy [36]. As a result of these ﬁndings,
adenosine has becomeof special interest in the search formore effective
treatments for GVHD.
The inﬂammatory reaction inGVHD is followed by the release of ATP
from dying cells. This ATP is converted to AMP and further to adenosine
by CD39 and CD73 respectively. This pathway has been shown to be es-
sential and exhibit a non-redundant role in inﬂammatory modulation
[26]. Increases in inﬂammatory tissue damage cause an increase in
adenosine release, which creates a negative feedback loop via the A2A
receptor. Released adenosine binds to A2A receptors on the cell surface
of alloreactive donor T cells and inhibits T cell activation by host antigen
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also essential in inducing the development of Tregs and increasing im-
mune tolerance [7,29]. Taking these results together, the A2A receptor
can mediate both innate and adaptive immune responses, reducing
alloreactive donor T cells and increasing overall Treg levels. It has been
shown that the number of Tregs found in the peripheral blood and
other affected tissues of patients are decreased in GVHD [37]. It is possi-
ble that this reduction in Tregs and increase in alloreactive donor T cells
observed in GVHD could be reversed by the administration of A2A recep-
tor agonists.
5. A2aR agonists and their application in GVHD
Those treatments that limit alloreactive T cell activation and/or
migration to affected tissues in GVHD have been the most promising
[38,39]. Agents that elevate cAMP have also been known to prevent
mortality andmorbidity inmurinemodels of GVHD [40]. The A2AR ago-
nist ATL146e, which activates the cAMP elevating G-coupled A2A recep-
tor, has been shown to protect a murine model of GVHD from disease
progression [3]. Acute GVHD was induced by transferring MHCI mis-
matched parental T lymphocytes into F1 recipients, causing extensive
donor cell engraftment, release of pro-inﬂammatory cytokines and
development of cytotoxic T lymphocytes against host allo-antigens
[41–43]. During 14-day subcutaneous treatment with ATL146e as a
GVHDpreventative treatment, weight loss and overallmortalitywas re-
duced in agonist treated mice over vehicle treated controls. In addition,
visible signs of GVHD, which include hunched posture, diarrhea and
skin inﬂammation, were all reduced. At themolecular level, alloreactive
donor T cell activation was also inhibited by ATL146e treatment. Pro-
inﬂammatory cytokine levels in blood serum were signiﬁcantly re-
duced below vehicle treated mice, with an accompanying increase in
the anti-inﬂammatory cytokine IL-10. Treatment of a GVHD model
with ATL146e 9 days after HSCT reversed weight loss, indicating that
ATL146e can also serve as a treatment for established GVHD. This
could be a very promising new treatment for patients who suffer from
steroid refractory GVHD, which is also usually unresponsive to other
more common GVHD treatments.
Further studies have helped to elucidate the relationship between
treatment with A2AR agonists and the immunosuppressive response.
The treatment of naïve CD4+CD25− mouse T cells in vitro with the
A2AR agonists ATL146e, ATL370 and ATL1223 have been shown to
enhance the TGFβ-induced generation of FoxP3+ Tregs [2]. When a
GVHD mouse model was similarly treated, there was signiﬁcant im-
provement in weight and mortality as well as inhibition of pro-
inﬂammatory cytokine and chemokine production. Most interesting
was the increase in FoxP3+ Tregs in agonist treated mice when com-
pared with vehicle controls. It was found that Tregs increased in agonist
treated mice were of donor origin, conﬁrming the requirement for the
development of functional Tregs from donor cells to prevent increased
mortality in GVHD. This increase of Tregs was observed not only in lym-
phoid tissues and blood, but also in two major target organs of GVHD,
the skin and colon, which both showed a marked improvement over
vehicle treated controls.
It was also observed that the pro-inﬂammatory cytokines GCSF and
IL-6 were reduced in serum after treatment, and that the tolerance-
inducing cytokine IL-10 was elevated. Possibly most important was
the observation that IFNγ production after restimulation is preserved
with ATL146e treatment, which could explain the lack of susceptibility
of these mice to infection even after long-term treatment with the
immunosuppressive A2A receptor agonist [3]. Since it has been ob-
served that long-term activation of A2A receptors on CD4+ T cells by
cAMP elevating agents results in sustained tolerance in CD4+ T cells
without impairing the immune response to non-speciﬁc mitogens, it
is likely that activation of the A2A receptor preserves T cell response
to global stimuli while preventing T-cell response to speciﬁc alloanti-
gens. This is an important observation, as it conﬁrms that long-termadministration of A2AR agonists does not cause inappropriate termina-
tion of immune responses despite the importance of A2AR activation in
the anti-inﬂammatory negative feedback loop.
Study of the A2AR pathway has determined that the activation of
A2AR results in a reduction of single positive CD4 or CD8 Teff cells,
which are responsible for the release of many pro-inﬂammatory cyto-
kines, and that T cells activated in the presence of A2AR agonists are un-
able to proliferate or produce IL-2 or IFNγ upon restimulation [3]. These
same Teff cells also show reduced proliferation in the presence of A2AR
agonists, reducing autoimmune responses from these cells [29]. In addi-
tion, A2AR agonists tend to produce Tregs that are responsible for induc-
tion of immune tolerance by reducing the production of IL-6 and
increasing the production of TGFβ, which also serves to further inhibit
the generation of adaptor T effector cells [2]. These recent studies have
shown that activation of the A2A receptor and downstream events
seems to be composed of two branches: (1) inhibition of donor T cell ac-
tivation and migration to target organs and (2) induction of anti-
inﬂammatory FoxP3+ regulatory T cells.
6. GVHD and A2AR agonists: mechanisms of function
Themechanismbehind the activity of A2AR agonists in GVHDhas not
yet fully been elucidated, butmuch is knownabout the activity of the re-
ceptor in other diseases. From studies performed using adenosine and
adenosine analogs, a mechanism can be proposed for the function of
A2AR agonists in GVHD. The A2A receptor, which is coupled to a Gs pro-
tein, is activated by the binding of the agonist, causing a signiﬁcant in-
crease in intracellular cAMP levels generated by adenylyl cyclase (AC)
during the inﬂammatory response (Fig. 1). This elevation of cAMP acti-
vates protein kinase A (PKA), which results in the phosphorylation
and activation of the cAMP response element-binding protein (CREB)
at Ser-133 [44]. CREB creates a complex with p300 and the nuclear
co-factor CBP, which in turn binds to cAMP responsive elements in the
promoter region of many genes, including the anti-inﬂammatory cyto-
kine IL-10. CREB has also been shown to promote TGFβmediated gener-
ation of FoxP3 Tregs [45–48]. Normally, the Treg-speciﬁc demethylated
region (TSDR) in the FoxP3 locus remains methylated in resting
T cells, preventing CREB from binding. TGFβ signaling removes this
methylation, allowing CREB to bind and transcribe FoxP3, promoting
the development and stabilization of Tregs.
In addition, CREB is able to indirectly modulate cytokine gene
expression through the inhibition of nuclear factor-κB (NF-κB) [49].
Blocking of the NF-κB pathway prevents the expression of many pro-
inﬂammatory cytokines including TNFα. Though the precise mecha-
nism is unclear, it is very likely that the inhibition of the NF-κB pathway
in conjunctionwith CREB-induced Treg production is the primarymeth-
od by which A2A receptor agonists prevent the release of tissue damag-
ing cytokines and reduce the severity of GVHD in murine models.
7. The future of A2AR agonists in GVHD treatment
Currently, themainstay of treatment for GVHDconsists of corticoste-
roids, often in conjunction with other immunosuppressants. While this
is effective in reducing the donor T cell reaction to host tissues, it is only
effective in 50% of patients and opens up the immune system for
secondary infection. There are also signiﬁcant side effects associated
with administration of these drugs. Data suggests that the use of A2AR
agonists in the clinic could increase donor immunotolerance to host tis-
sues while maintaining an immune response to foreign pathogens. The
majority of deaths in GVHD patients are a result of unrelated infections
that formas a result of suppressed immune systems aswell as due to the
immune dysregulation caused by the GVHD itself. Implementation of
A2AR agonists in the clinic either in conjunction with corticosteroids,
or hopefully as a steroid sparing agent, may provide a novel prevention
or treatment strategy that both prevents or treats GVHD and reduces
the risk of infection.
Fig. 1. A proposed mechanism for the adenosine A2AR agonist mediated activation of the cAMP–CREB pathway and induction of immune tolerance. The agonist binds to the A2A receptor
and activates the Gs protein. The activated Gs protein interacts with adenylyl cyclase (AC), which converts ATP to cAMP. Elevation of intracellular cAMP levels activates protein kinase A
(PKA),which phosphorylates the cAMP response element binding protein (CREB) at Ser-133. The phosphorylated CREB expresses a dual function in promoting tolerance. First, by forming
a complexwith p300 and the nuclear co-factor CBP, CREB is able to bind to CREB response elements (CREs) and activate transcription of anti-inﬂammatory cytokines such as IL-10 as well
as increasing the expression and number of FoxP3+ Tregs. Secondly, activated CREB blocks the NF-κB pathway, which is responsible for the transcription of pro-inﬂammatory cytokines
such as IL-1, IL-6 and TNFα.
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these agents are promising as a therapeutic treatment for GVHD.
Despite this, there are still questions to be answered, and determining
the exact mechanism by which this immune tolerance is activated will
be important to improving the quality and potency of future agents.
Two obstacles in particular stand in the way of pharmacologic progress
with A2AR agonists: (1) A2AR agonists tend to have very short half-lives,
which results in the need for additional treatments to replenish active
drug levels and (2) A2AR are abundant on many cell types, including
those found in the brain and heart, and the speciﬁcity is a concern
for A2AR agonists to prevent neuro- or cardiotoxicity. These concerns
have recently been addressed in a study involving the attachment of a
small Fc domain protein to the A2AR agonist, conferring stability and
preventing non-speciﬁc binding of the agent [50]. In this study, the Fc
bound agonist was able to successfully treat a murine model of pneu-
monitis to an equivalent efﬁciency as that of an unbound agonist. In ad-
dition, only low levels of Fc bound agonist were detectable in the heart
and brain of treated mice, showing high speciﬁcity of the Fc domain for
areas of inﬂammation. This method of conjugating A2AR agonists to the
Fc domain is another step towards creating agents for the treatment
and/or prevention of GVHD in human patients and may also serve as a
general method to target delivery of small molecule drugs to areas of
inﬂammation.
A2A receptor agonists, through activation of Tregs and immune toler-
ance, have proven to be effective in reducing and preventing GVHD de-
velopment in murine models of the disease. These results suggest that
A2AR agonists have therapeutic potential for the treatment of acute
GVHD in human patients and possibly other autoimmune disorders.
Currently, humanized mouse models are being developed to furtherelucidate the effects of A2AR agonists in a model more reﬂective of the
human immune system. These models will also help us to determine
the effects of long term administration of adenosine receptor activation
by A2AR agonists in human immune cells. These newmodels, alongwith
the development of more human speciﬁc compounds, will lead us
forward in creating clinical agents for use in phase 1 and phase 2 patient
studies.
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